Related Experiment Video
Updated: May 13, 2026
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
Efficiency of noopept in streptozotocin-induced diabetes in rats
R U Ostrovskaya1, I V Ozerova, T A Gudascheva
1V.V. Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia. rita.ostrovskaya@gmail.com
Abstract:
We studied the effects of new nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) in various dosage regimens on the dynamics of glycemia, body weight, and pain sensitivity in rats receiving diabetogenic toxin streptozotocin. In experimental diabetic rats, Noopept alleviated glycemia and weight loss and normalized enhanced pain sensitivity. The normalizing effect of Noopept was most pronounced when it was administered as a preventive agent prior to injection of the toxin. Both preventive and therapeutic administration of Noopept (delayed injections included) significantly weakened the examined metabolic effects of diabetogenic toxin. Possible mechanisms of the antidiabetic action of Noopept are analyzed.
Insights
New nootropic drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) showed significant antidiabetic effects in streptozotocin-induced diabetic rats. It normalized glycemia, weight loss, and pain sensitivity, especially when used preventively.
Area of Science:
- Neuroscience
- Pharmacology
- Endocrinology
Background:
- Streptozotocin (STZ) is a diabetogenic toxin used to induce diabetes in animal models.
- Nootropic drugs, like Noopept, are known for their cognitive-enhancing and neuroprotective properties.
- The metabolic and pain-related effects of STZ-induced diabetes require effective therapeutic interventions.
Purpose of the Study:
- To investigate the effects of Noopept on glycemia, body weight, and pain sensitivity in STZ-induced diabetic rats.
- To evaluate the efficacy of Noopept across various dosage regimens and administration timings (preventive vs. therapeutic).
- To explore potential mechanisms underlying Noopept's antidiabetic action.
Main Methods:
- Experimental induction of diabetes in rats using streptozotocin.
- Administration of Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) in different doses and schedules.
- Monitoring of key metabolic parameters: glycemia and body weight.
- Assessment of pain sensitivity using established animal testing protocols.
Main Results:
- Noopept significantly alleviated hyperglycemia and prevented weight loss in diabetic rats.
- Enhanced pain sensitivity in diabetic rats was normalized by Noopept administration.
- The most pronounced effects were observed when Noopept was administered preventively before STZ injection.
- Both preventive and therapeutic Noopept treatments (including delayed) mitigated the metabolic disturbances caused by STZ.
Conclusions:
- Noopept demonstrates significant antidiabetic and analgesic properties in a rat model of diabetes.
- Preventive administration of Noopept appears to be particularly effective in mitigating STZ-induced metabolic dysfunction.
- Noopept holds potential as a therapeutic agent for managing diabetes and associated pain, warranting further investigation into its mechanisms.
